EyePoint Pharmaceuticals Inc
EYPT13.300USD
+0.570+4.48%
終値 02/06, 16:00（ET）15分遅れの株価
925.28M時価総額
損失額直近12ヶ月PER
詳細情報 EyePoint Pharmaceuticals Inc 企業名
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Incの企業情報
企業コードEYPT
会社名EyePoint Pharmaceuticals Inc
上場日Jan 27, 2005
最高経営責任者「CEO」Duker (Jay S)
従業員数165
証券種類Ordinary Share
決算期末Jan 27
本社所在地480 Pleasant Street, Suite C400
都市WATERTOWN
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02472
電話番号16179265000
ウェブサイトhttps://eyepointpharma.com/
企業コードEYPT
上場日Jan 27, 2005
最高経営責任者「CEO」Duker (Jay S)
EyePoint Pharmaceuticals Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
753.40K
+67787.00%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
653.26K
+87799.00%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+121464.00%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+2000.00%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
+45014.00%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
39.06K
--
Dr. Goeran A. Ando, M.D.
Dr. Goeran A. Ando, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George Elston
Mr. George Elston
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Stern
Mr. Stern
Investor Relations
Investor Relations
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
753.40K
+67787.00%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
653.26K
+87799.00%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+121464.00%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+2000.00%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
+45014.00%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
39.06K
--
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
YUTIQ
3.10M
7.16%
地域別USD
会社名
収益
比率
United States
42.05M
97.17%
China
1.12M
2.60%
United Kingdom
100.00K
0.23%
事業別
地域別
事業別USD
会社名
収益
比率
YUTIQ
3.10M
7.16%
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
Cormorant Asset Management, LP
9.98%
Suvretta Capital Management, LLC
7.48%
Adage Capital Management, L.P.
6.72%
The Vanguard Group, Inc.
5.82%
BlackRock Institutional Trust Company, N.A.
5.17%
他の
64.82%
株主統計
株主統計
比率
Cormorant Asset Management, LP
9.98%
Suvretta Capital Management, LLC
7.48%
Adage Capital Management, L.P.
6.72%
The Vanguard Group, Inc.
5.82%
BlackRock Institutional Trust Company, N.A.
5.17%
他の
64.82%
種類
株主統計
比率
Hedge Fund
32.77%
Investment Advisor
25.06%
Investment Advisor/Hedge Fund
20.85%
Research Firm
4.43%
Private Equity
3.39%
Individual Investor
2.96%
Venture Capital
2.58%
Bank and Trust
1.06%
Pension Fund
0.13%
他の
6.78%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
363
69.86M
126.07%
--
2025Q3
373
69.94M
127.01%
+1.23K
2025Q2
381
69.95M
127.71%
-5.27M
2025Q1
371
75.32M
126.89%
-11.89M
2024Q4
359
75.24M
109.81%
+11.20M
2024Q3
343
59.71M
126.62%
+193.11K
2024Q2
330
60.06M
120.79%
+1.75M
2024Q1
313
56.72M
108.78%
+2.51M
2023Q4
268
50.21M
76.86%
+16.41M
2023Q3
224
33.81M
98.97%
+2.98M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Cormorant Asset Management, LP
8.27M
9.98%
-60.00K
-0.72%
Dec 04, 2025
Suvretta Capital Management, LLC
6.19M
7.48%
-611.38K
-8.99%
Sep 30, 2025
Adage Capital Management, L.P.
5.56M
6.72%
-1.24M
-18.24%
Sep 30, 2025
The Vanguard Group, Inc.
3.79M
4.58%
-8.13K
-0.21%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.28M
5.17%
-316.39K
-6.88%
Sep 30, 2025
Franklin Advisers, Inc.
4.14M
5%
-130.85K
-3.07%
Sep 30, 2025
Federated Hermes Global Investment Management Corp.
3.58M
4.32%
-1.46K
-0.04%
Sep 30, 2025
TCG Crossover Management, LLC
3.57M
4.32%
--
--
Sep 30, 2025
Citadel Advisors LLC
2.14M
2.58%
-208.82K
-8.91%
Sep 30, 2025
Paradigm BioCapital Advisors LP
2.01M
2.42%
+2.01M
--
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
1%
Simplify Health Care ETF
0.99%
State Street SPDR S&P Pharmaceuticals ETF
0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.95%
Invesco Dorsey Wright SmallCap Momentum ETF
0.36%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares Micro-Cap ETF
0.15%
iShares Health Innovation Active ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.09%
詳細を見る
Virtus LifeSci Biotech Clinical Trials ETF
比率1%
Simplify Health Care ETF
比率0.99%
State Street SPDR S&P Pharmaceuticals ETF
比率0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率0.95%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.36%
Federated Hermes MDT Small Cap Core ETF
比率0.3%
iShares Micro-Cap ETF
比率0.15%
iShares Health Innovation Active ETF
比率0.15%
ProShares Ultra Nasdaq Biotechnology
比率0.12%
Invesco Nasdaq Biotechnology ETF
比率0.09%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
日付
配当落ち日
種類
比率
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
